Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
NCT ID: NCT02089789
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2014-03-07
2030-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Proteins, fats, and other molecules are the body s building blocks. Many of these molecules must have sugars, or chains of sugars, attached to work properly. People with congenital disorders of glycosylation (CDGs) cannot attach these sugars or sugar chains properly. A child or adult with a CDG can have symptoms in different parts of the body, including brain, nerves, muscles, liver, and immune system. Researchers want to learn more about these diseases to understand better what is causing the problems.
Objective:
\- To learn more about CDGs.
Eligibility:
\- People 1 month to 2 years old may be seen as outpatients or by telehealth. Patients 2-80 years with CDG or suspected to have a CDG may be seen under this protocol as inpatients, outpatients or by teleheath.
Design:
* CDG participants may be seen as inpatients, outpatients or by teleheath. Inpatient stays may last 2-5 days.
* They will have:-Medical history and physical exam. They will answer questions about their CDG.
* Blood taken several times. Their skin will be numbed, then a needle will take blood from an arm vein.
* Samples taken of their skin, urine, and maybe stool and spinal fluid.
* Photos taken of their whole body. They can wear underwear and cover their eyes.
* Brain MRI. They will lie on a table that slides in and out of a metal cylinder. The scanner makes loud knocking noises so they can wear earplugs.
* Abdomen ultrasound. Sound waves take images of the body from the outside.
* Hand/wrist X-rays for young patients. They may have a full-body X-ray.
* DEXA bone density scan. Participants will lie on a table under a scanner.
* Echocardiogram and electrocardiogram for heart activity. Pads are stuck on the skin and the electrical activity of the heart is recorded.
* Tests of hearing, thinking, motor skills, and speech.
* Children participants may have tests done under sedation if it will benefit them directly.
* CDG participants may have other procedures during their visit. They may have follow-up visits every year.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this protocol, we propose to characterize the etiology and natural history of known, suspected or secondary CDGs to expand our knowledge about these disorders and provide access to patients of interest for research, teaching, and clinical experience.
Objectives:
The overall aim of this protocol is to advance our knowledge of primary, new, and secondary congenital disorders of glycosylation.
Study Population:
Participants 1 month or older will have been or will be referred to this protocol with a known or suspected CDG though only participants older than 2 years old will be evaluated as inpatients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CDG
Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Some participants will be relatives of patients with known CDG s, and their specimens will be obtained for the purpose of heterozygote testing and to serve as controls to help diagnose the proband. Participants may be seen as inpatients, outpatients or via Telehealth. In some cases, biologic samples may be obtained remotely and sent to the Gahl lab.
Exclusion Criteria
* Participants over two years of age will not be admitted if they are medically unstable and do not require admission to the Clinical Center for diagnosis.
* Pregnant women and newborns are excluded.
1 Month
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Human Genome Research Institute (NHGRI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lynne A Wolfe, C.R.N.P.
Role: PRINCIPAL_INVESTIGATOR
National Human Genome Research Institute (NHGRI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lynne Wolfe, M.S.
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-HG-0071
Identifier Type: -
Identifier Source: secondary_id
140071
Identifier Type: -
Identifier Source: org_study_id